Latest News

Lytix Biopharma AS appoints Øystein Rekdal as the new CEO

Lytix Biopharma announces two recent publications on LTX-401, a second generation molecule developed for treatment of visceral tumors

Intratumoral treatment with LTX-315 causes regression of Desmoid Tumor- A case history

Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma joins Lytix as Company Strategic Advisors and in SAB